Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘Powerful’ Study

Evangelos Terpos,Emmanouil Spanoudakis,Christos Poziopoulos,Argiris Symeonidis,Christos Georgopoulos,Eirini Katodritou,Panagiotis Zikos,George Vassilopoulos,Anastasia Pouli,Vassiliki Pappa,Panagiotis Repousis,Evridiki Michali,Evdoxia Hatjiharissi,Chrysavgi Lalayanni,Petros Patos,Gerassimos A Pangalis ,Helen Α Papadaki ,Kiki Karvounis‐Marolachakis ,Marie‐Christine Kyrtsonis ,Theodora Assimakopoulou,Magda Dadakaridou

doi:10.1182/blood-2020-138390

Abstract

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘Powerful’ Study

Highlights

Multiple myeloma (MM), a hematological malignancy associated with significant morbidity and mortality, is characterized by clonal plasma cell expansion in the bone marrow, presence of monoclonal immunoglobulin in the serum or urine, lytic bone lesions, hypercalcemia, renal insufficiency, anemia, and immunodeficiency
10%, we considered 100 patients to be adequate in order to ensure the aforementioned sample size for the final statistical analysis
In the present real-world study conducted in Greece, POM/LoDex demonstrated a long progression-free survival (PFS) when administered to patients with RRMM and at least two prior lines of therapy

Summary

Introduction

Multiple myeloma (MM), a hematological malignancy associated with significant morbidity and mortality, is characterized by clonal plasma cell expansion in the bone marrow, presence of monoclonal immunoglobulin in the serum or urine, lytic bone lesions, hypercalcemia, renal insufficiency, anemia, and immunodeficiency. Effective treatment of early relapses with therapeutic approaches that provide direct tumoricidal effects and suppress residual disease via immune mechanisms of action is critical in order to delay the onset of subsequent relapses [7,8]. Pomalidomide (POM), along with thalidomide and lenalidomide (LEN), belongs to the class of IMiDs. The drug has pleiotropic functions, via induction of myeloma cell apoptosis, inhibition of angiogenesis, and immunomodulation, and it targets tumor cells, and the bone marrow microenvironment [9]. All three IMiDs exert their activity by binding to cereblon (CRBN), a protein component of the CRL4 E3 ligase complex [10], inducing its interaction with the transcriptional factors Aiolos and Ikaros [11]

Methods

Results

Discussion

Conclusion